Effects of specific antiretroviral drugs on CVD risk and factors linked to accelerated CVD*
| Antiretroviral | CVD risk | ||||||
| ART class† | Clinical | Surrogate markers | Lipids | Platelet activation | Autophagy | ROS production | |
| Ritonavir (RTV) | PI | + | + | ↑ | + | Blocks | + |
| Lopinavir/RTV | PI | + | + | ↑ | + | Blocks | + |
| Darunavir/RTV | PI | + | + | +/− | + | Blocks | + |
| Atazanavir/RTV | PI | − | + | +/− | + | Induces | − |
| Atazanavir | PI | − | + | +/− | + | Induces | − |
| Abacavir | NRTI | +/− | + | − | + | Not tested | − |
| Raltegravir | INSTI | − | − | − | − | Not tested | − |
*Citations for these analyses are presented in the text. The methodology for assessment of platelet activation varied among studies.
†INSTI, integrase strand transfer inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ROS, reactive oxygen species.